FDA considering accelerated approval of new Alzheimer?s drug
FDA considering accelerated approval of new Alzheimer?s drug

FDA considering accelerated approval of new Alzheimer?s drug

The FDA is considering accelerated approval of a new drug shown to attack amyloid plaque in the human brain, a contributing cause of cognitive dysfunction in dementia and Alzheimer?s disease.� The FDA is expected to reach a decision by Friday, January 6.

Top Videos